Commentary

Cangrelor's success rose from prior failure


 

CHAMPION "is a strikingly important study. It has global implications for the way we treat patients. The rapid on and off deals with a lot of clinical scenarios we face all the time," said Dr. Martin Leon, an interventionalist at Columbia University.

"Sometimes we need to wait 5-7 days before a patient can go to surgery because of the increased risk of bleeding" following treatment with an oral antiplatelet drug, said Dr. Cindy Grines, an interventionalist at Detroit Medical Center. "This will have a huge impact."

Dr. Bhatt, Dr. Mehran, and Dr. Grines reported financial ties with several pharmaceutical companies, including the Medicines Company, which is developing cangrelor. Dr. Harrington and Dr. Stone reported ties with numerous drug companies, including receiving a research grant from the Medicines Company. Dr. Leon disclosed having ties to two device makers but no pharmaceutical companies.

Pages

Recommended Reading

Post-stent regimen leaves out aspirin in AF
MDedge Cardiology
Comparing imaging technologies for chest pain in ED
MDedge Cardiology
Heart teams inch into routine cardiac practice
MDedge Cardiology
Poor outcomes seen after carotid intervention non-ST-elevation MI
MDedge Cardiology
Atrial fibrillation device among top trials at ACC 13
MDedge Cardiology
Important valve replacement data expected at ACC.13
MDedge Cardiology
Straight talk partially counters bias towards PCI
MDedge Cardiology
Study identifies systolic window for high-risk patients
MDedge Cardiology
Greek financial crisis increased heart attacks
MDedge Cardiology
TERISA targets diabetes as potential new market for ranolazine
MDedge Cardiology